Journals / Türk Onkoloji Dergisi / 2021 / Cilt: 36 - Sayı: 3

Retroperitoneal Unicentric Castleman’s Disease

Pages
407–408
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Retroperitoneal localization is extremely rare.[10]

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Dear Editor, Castleman’s disease (CD) is an unusual lymphoproliferative disorder first described in 1954 by Benjamin and Virginia.[1] The etiology of the disease is not clear, however, the role of chronic inflammation, immunosuppression, disruption in the production of interleukin 6, and human herpesvirus 8 has been demonstrated.
📊
Key Findings & Data:Histologically, there are four subtypes; hyaline vascular, plasma cell variant, multicentric (mixed), and plasmablastic variant.[2] Hyaline vascular CD is characterized by prominent vascular proliferation and hyalinization of the vessel walls.
💡
Conclusion & Impact:Retroperitoneal localization is extremely rare.[10]
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Dear Editor, Castleman’s disease (CD) is an unusual lymphoproliferative disorder first described in 1954 by Benjamin and Virginia.[1] The etiology of the disease is not clear, however, the role of chronic inflammation, immunosuppression, disruption in the production of interleukin 6, and human herpesvirus 8 has been demonstrated. Histologically, there are four subtypes; hyaline vascular, plasma cell variant, multicentric (mixed), and plasmablastic variant.[2] Hyaline vascular CD is characterized by prominent vascular proliferation and hyalinization of the vessel walls. Lymphoid follicles have atretic germinal centers traversed by penetrating vessels that are called “lollipop follicle.” Thickened mantle zones consisting of lymphocytes arranged in layers-onion skin appearance are present throughout the lymph node. Fused mantle zones that contain more than one germinal center can be observed. Extensive vascular proliferation with perivascular hyalinization is evident in the interfollicular areas.[3,4] There are two subtypes clinically, unicentric CD (UCD) and multicentric CD (MCD). UCD typically presents as singular enlarged of lymph node. About 70% of all CD patients are in this group. UCD is often found in both males and females aged 20-30 years and presents asymptomatically.[ 5] MCD is a widespread disease associated with systemic symptoms.[6] Patients of the UCD usually have a good prognosis and are treated with surgical excision.[6] MCD tends to behave aggressively, similarly to lymphoma, and is treated with immunotherapy, chemotherapy, and radiotherapy.[7-9] CD most commonly develops in the mediastinum and the second most common localization cervical region. Retroperitoneal localization is extremely rare.[10]

🔖

Cite This Article

DEMİREL, S., TOSUNER, Z., ALİYAZICIOĞLU, T. (2022). Retroperitoneal Unicentric Castleman’s Disease. Türk Onkoloji Dergisi, Cilt: 36 - Sayı: 3, 407–408. https://ajindex.com/articles/639096

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Benjamin C, Virginia WT. CASE records of the Massachusetts general hospital weekly clinicopathological exercises: Case 40011. N Engl J Med 1954;250(1):26–30
  2. Saeed-Abdul-Rahman I, Al-Amri AM. Castleman disease. Korean J Hematol 2012;47(3):163–77
  3. Wu D, Sihia M, Jaffe ES. Pathology of castleman disease. Hematol Oncol Clin N Am 2018;32(1):37–52
  4. Wang HW, Pittaluga S, Jaffe ES. Multicentric castleman disease, where are we now? Semin Diagn Pathol 2016;33(5):294–306
  5. Shah D, Darji P, Lodha S, Bolla S. Unicentric Castleman’s disease of abdomen. J Radiol Case Rep 2013;7(3):26–33
  6. Bucher P, Chassot G, Zufferey G, Ris F, Huber O, Morel P. Surgical management of abdominal and retroperitoneal Castleman’s disease. Worl J Surg Oncol 2005;3:33
  7. Guo H, Shen Y, Wang WL, Zhang M, Li H, Wu YS, et al. Castleman diseasemimicked pancreatic carcinoma: report of two cases. World J Surg Oncol 2012;10:154
  8. Shimokiharaa K, Kawaharab T, Kasaharaa R, Kasugaa J, Sugiuraa S, Tajiric R, et al. Retroperitoneal Castleman’s disease. Case Rep Oncol 2019;12(3):885–9
  9. Kim TJ, Han JK, Kim YH, Kim TK, Choi BI. Castleman disease of theabdomen: İmaging spectrum and clinicopathologic correlations. J Comput Assist Tomogr 2001;25(2):207–14
  10. Nakata K, Iwahashi N, Matsukawa H, Noguchi T, Yahata A, Ota N, et al. Laparoscopically resected Castleman’s disease in the pelvic retroperitoneum: A case report. Mol Clin Oncol 2020;12(2):169–73
  11. Shahidi H, Myers JL, Kvale PA. Castleman’s disease. Mayo Clin Proc 1995;70(10):969–77
  12. Roca B. Castleman’s disease. A review. AIDS Rev 2009;11(1):3–7
  13. Horster S, Jung C, Zietz C, Cohen CD, Siebeck M, Goebel FD. AIDS, multicentric Castleman’s disease, and plamablastic leukemia: Report of along-term survival. Infection 2004;32(5):296–8.